Fibroheal Woundcare Profile
Key Indicators
- Authorised Capital ₹ 3.25 Cr
as on 15-11-2024
- Paid Up Capital ₹ 1.15 Cr
as on 15-11-2024
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 Cr
as on 15-11-2024
- Revenue 195.05%
(FY 2023)
- Profit 30.48%
(FY 2023)
- Ebitda 43.60%
(FY 2023)
- Net Worth 98.73%
(FY 2023)
- Total Assets 60.22%
(FY 2023)
About Fibroheal Woundcare
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.25 Cr and a paid-up capital of Rs 1.15 Cr.
The company currently has active open charges totaling ₹3.00 Cr.
Bharat Tandon, Subramanian Shivaraman, and Vivek Mishra serve as directors at the Company.
- CIN/LLPIN
U74999KA2017PTC101983
- Company No.
101983
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 2017
- Date of AGM
16 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Fibroheal Woundcare Private Limited offer?
Fibroheal Woundcare Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Nutraceuticals & Dietary Supplements, Fitness Supplements.
Who are the key members and board of directors at Fibroheal Woundcare?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharat Tandon  | Director | 06-Apr-2017 | Current |
| Subramanian Shivaraman | Nominee Director | 27-Dec-2018 | Current |
| Vivek Mishra | Director | 06-Apr-2017 | Current |
Financial Performance of Fibroheal Woundcare.
Fibroheal Woundcare Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 195.05% increase. The company also saw a substantial improvement in profitability, with a 30.48% increase in profit. The company's net worth Soared by an impressive increase of 98.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fibroheal Woundcare?
In 2023, Fibroheal Woundcare had a promoter holding of 61.28% and a public holding of 38.72%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Oct 2023 | ₹3.00 Cr | Open |
How Many Employees Work at Fibroheal Woundcare?
Fibroheal Woundcare has a workforce of 29 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fibroheal Woundcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fibroheal Woundcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
